Man Group’s ArriVent BioPharma AVBP Stock Holding History

Man Group’s Portfolio AVBP Stock Details AVBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-20,727	Closed	-$478K	–	2664
2026 Q1	$478K	Buy	+20,727	New	+$468K	﹤0.01%	2092

Other funds holding AVBP

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

IAM

Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Man Group's AVBP Position: Q2 2026 in Review

Man Group sold out of ArriVent BioPharma (AVBP) in Q2 2026, closing a stake of 20,727 shares — an estimated $478K sold.

Man Group first reported a position in AVBP in Q1 2026 and held it in 1 quarter. The position peaked at $478K in Q1 2026. 158 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

Man Group reported no remaining ArriVent BioPharma position as of Q2 2026 after selling out during the quarter.
Man Group sold 20,727 ArriVent BioPharma shares in Q2 2026, an estimated $478K.
Man Group first reported a position in ArriVent BioPharma in Q1 2026 and held it in 1 quarter.
Man Group's ArriVent BioPharma position peaked at $478K in Q1 2026.
158 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Man Group's 13F filing for Q2 2026, filed 14 Aug 2026.